Citations

Mayo Clinic

Showing 10 of 108523 citations.

Normal Villous Architecture With Increased Intraepithelial Lymphocytes
Patterson, Emily R., Shmidt, Eugenia , Smyrk, Thomas C. , Enders, Felicity T, Oxentenko, Amy S. , Enders, Felicity

American Journal of Clinical Pathology | February 26, 2015 | Volume: 143 | Issue: 3 | Pages: 445-450

10.1309/ajcpbkqnd4shvx9q | PMID 25696804 Get It

Saccadic palsy following cardiac surgery: a review and new hypothesis
Eggers, Scott D.Z. , Roeber, Sigrun, Härtig, Wolfgang, Nair, Govind , Reich, Daniel S. , Horn, Anja K. E. , Leigh, Richard J. , Nair, Govind

Annals of the New York Academy of Sciences | February 26, 2015 | Volume: 1343 | Issue: 1 | Pages: 113-119

10.1111/nyas.12666 | PMID 25721480 Get It

The ocular motor system provides several advantages for studying the brain, including well‐defined populations of neurons that contribute to specific eye movements. Generation of rapid eye movements (saccades) depends on excitatory burst neurons (EBN) and omnipause neurons (OPN) within the brainstem, both types of cells are highly active. Experimental lesions of EBN and OPN cause slowing or complete loss of saccades. We report a patient who developed a permanent, selective saccadic palsy following cardiac surgery. When she died several years later, surprisingly, autopsy showed preservation of EBN and OPN. We therefore considered other mechanisms that could explain her saccadic palsy. Recent work has shown that both EBN and OPN are ensheathed by perineuronal nets (PN), which are specialized extracellular matrix structures that may help stabilize synaptic contacts, promote local ion homeostasis, or play a protective role in certain highly active neurons. Here, we review the possibility that damage to PN, rather than to the neurons they support, could lead to neuronal dysfunction—such as saccadic palsy. We also suggest how future studies could test this hypothesis, which may provide insights into the vulnerability of other active neurons in the nervous system that depend on PN.
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
Pungpapong, Surakit , Aqel, Bashar , Leise, Michael D. , Werner, K. Tuesday , Murphy, Jennifer L. , Henry, Tanisha M., Ryland, Kristen, Chervenak, Amy, Watt, Kymberly D. , Vargas, Hugo E. , Leise, Michael, Chervenak, Amy E, Aqel, Bashar A. , Keaveny, Andrew P. , Vargas, Hugo E , Pungpapong, Surakit , Werner, Kristina Tuesday

Hepatology | February 26, 2015 | Volume: 61 | Issue: 6 | Pages: 1880-1886

10.1002/hep.27770 | PMID 25722203 Get It

Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with minimal adverse events in non–liver transplant (LT) patients with hepatitis C virus (HCV) genotype 1 infection. This is the first multicenter report on the efficacy, safety, and tolerability of this regimen in LT recipients. A total of 123 patients (76% male, 74% white, 60% genotype 1a, 30% METAVIR F3‐F4, 4% decompensation, 11% cholestatic recurrence, 7% had kidney transplant, and 82% previously failed pegylated interferon/RBV‐based regimens) received treatment and were followed for a median of 30 weeks (range 12‐53 weeks). The median time from LT to treatment was 32 months (range 2‐317 months). Tacrolimus was the primary immunosuppression in 91% of patients. Minimal immunosuppression dose adjustments were required. An SVR 12 weeks after treatment completion (SVR12) was achieved in 90% of patients (95% confidence interval 84%‐96%). In patients with genotype 1a infection, the SVR12 rate was significantly lower in those with METAVIR F3‐F4 (71%) compared to those with F0‐F2 (91%). Half of the patients achieved undetected HCV RNA at treatment week 4, and their SVR12 rate was significantly higher (96%) compared to those with detectable HCV RNA (83%). Treatment was very well tolerated with mild degrees of adverse events, except for one death possibly due to drug‐induced lung injury. In the 25 patients who received RBV, 72% developed anemia requiring intervention. Conclusion : An all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without RBV for 12 weeks was very well tolerated and resulted in excellent SVR12 rates in LT recipients with HCV genotype 1 infection. (H epatology 2015;61:1880–1886)
Activities of Daily Living and Outcomes in Heart Failure
Manemann, Sheila M., Chamberlain, Alanna M. , Jiang, Ruoxiang , Weston, Susan A., Roger, Véronique L. , Dunlay, Shannon M. , Cheville, Andrea , Chamberlain, Alanna M

Circulation: Heart Failure | February 26, 2015 | Volume: 8 | Issue: 2 | Pages: 261-267

10.1161/circheartfailure.114.001542 | PMID 25717059 Get It

Background— Chronic disease can contribute to functional disability, which can degrade quality of life. However, the prevalence of functional disability and its association with outcomes among patients with heart failure requires further study. Methods and Results— Southeastern Minnesota residents with heart failure were enrolled from September 2003 through January 2012 into a cohort study with follow-up through December 2012. Difficulty with 9 activities of daily living (ADLs) was assessed by a questionnaire. Patients were divided into 3 categories of ADL difficulty (no/minimal, moderate, severe). The associations of ADL difficulty with mortality and hospitalization were assessed using Cox and Andersen-Gill models. Among 1128 patients (mean age, 74.7 years; 49.2% female), a majority (59.4%) reported difficulty with one or more ADLs at enrollment, with 272 (24.1%) and 146 (12.9%) experiencing moderate and severe difficulty, respectively. After a mean (SD) follow-up of 3.2 (2.4) years, 614 patients (54.4%) had died. Mortality increased with increasing ADL difficulty; the hazard ratio (95% confidence interval) for death was 1.49 (1.22–1.82) and 2.26 (1.79–2.86) for those with moderate and severe difficulty, respectively, compared to those with no/minimal difficulty ( P trend <0.001). Patients with moderate and severe difficulty were at an increased risk for all-cause and noncardiovascular hospitalization. In a second assessment, 17.7% of survivors reported more difficulty with ADLs and patients with persistently severe or worsening difficulty were at an increased risk for death (hazard ratio, 2.10; 95% confidence interval, 1.71–2.58; P <0.001) and hospitalization (hazard ratio, 1.51; 95% confidence interval, 1.31–1.74; P <0.001). Conclusions— Functional disability is common in patients with heart failure, can progress over time, and is associated with adverse prognosis.
Secondary Prevention Strategy of Cardiovascular Disease Using Endothelial Function Testing
Matsuzawa, Yasushi , Kwon, Taek‐Geun , Lerman, Lilach O. , Guddeti, Raviteja , Lerman, Amir

Circulation Journal | February 26, 2015 | Volume: 79 | Issue: 4 | Pages: 685-694

10.1253/circj.cj-15-0068 | PMID 25740088 Get It

Adoptive cell transfer in autoimmune hepatitis
Czaja, Albert J.

Expert Review of Gastroenterology & Hepatology | February 26, 2015 | Volume: 9 | Issue: 6 | Pages: 821-836

10.1586/17474124.2015.1019470 | PMID 25719553 Get It

Gained in Translation
Lerman, Lilach O. , Textor, Stephen C.

Hypertension | February 26, 2015 | Volume: 65 | Issue: 5 | Pages: 976-982

10.1161/hypertensionaha.114.04364 | PMID 25712725 Get It

Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting
Iqbal, Javaid , Holmes, David R. , Morice, Marie‐Claude, Mack, Michael J. , Feldman, Ted , Ståhle, E, Escaned, Javier , Banning, Adrian , Gunn, Julian , Colombo, Antonio , Mohr, Friedrich W., Zhang, Yao‐Jun , Kappetein, Arie Pieter, Stahle, Elizabeth, Banning, Adrian P, Gunn, Julian P, Steyerberg, Ewout W. , Serruys, Patrick W. , Kappetein, A. Pieter , Escaned, Javier , Banning, Adrian

Circulation | February 26, 2015 | Volume: 131 | Issue: 14 | Pages: 1269-1277

10.1161/circulationaha.114.013042 | PMID 25847979 Get It

Background— There is a paucity of data on the use of optimal medical therapy (OMT) in patients with complex coronary artery disease undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting (CABG) and its long-term prognostic significance. Methods and Results— The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicenter, randomized, clinical trial of patients (n=1800) with complex coronary disease randomized to revascularization with percutaneous coronary intervention or CABG. Detailed drug history was collected for all patients at discharge and at the 1-month, 6-month, 1-year, 3-year, and 5-year follow-ups. OMT was defined as the combination of at least 1 antiplatelet drug, statin, β-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Five-year clinical outcomes were stratified by OMT and non-OMT. OMT was underused in patients treated with coronary revascularization, especially CABG. OMT was an independent predictor of survival. OMT was associated with a significant reduction in mortality (hazard ratio, 0.64; 95% confidence interval, 0.48–0.85; P =0.002) and composite end point of death/myocardial infarction/stroke (hazard ratio, 0.73; 95% confidence interval, 0.58–0.92; P =0.007) at the 5-year follow-up. The treatment effect with OMT (36% relative reduction in mortality over 5 years) was greater than the treatment effect of revascularization strategy (26% relative reduction in mortality with CABG versus percutaneous coronary intervention over 5 years). On stratified analysis, all the components of OMT were important for reducing adverse outcomes regardless of revascularization strategy. Conclusions— The use of OMT remains low in patients with complex coronary disease requiring coronary intervention with percutaneous coronary intervention and even lower in patients treated with CABG. Lack of OMT is associated with adverse clinical outcomes. Targeted strategies to improve OMT use in postrevascularization patients are warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00114972.
Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
Hensley, Martee L. , Miller, Austin , O’Malley, David M. , Mannel, Robert S., Behbakht, Kian, Michael, Helen, Behbakht, Kian , Bakkum‐Gamez, Jamie N. , Michael, Helen , Miller, Austin , O'Malley, David M

Journal of Clinical Oncology | February 26, 2015 | Volume: 33 | Issue: 10 | Pages: 1180-1185

10.1200/jco.2014.58.3781 | PMID 25713428 Get It

Purpose Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients with uterine leiomyosarcoma (uLMS). This study aimed to determine whether the addition of bevacizumab to gemcitabine-docetaxel increases progression-free survival (PFS) in uLMS. Patients and Methods In this phase III, double-blind, placebo-controlled trial, patients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-docetaxel plus bevacizumab or gemcitabine-docetaxel plus placebo. PFS, overall survival (OS), and objective response rates (ORRs) were compared to determine superiority. Target accrual was 130 patients to detect an increase in median PFS from 4 months (gemcitabine-docetaxel plus placebo) to 6.7 months (gemcitabine-docetaxel plus bevacizumab). Treatment effects on PFS and OS were described by hazard ratios (HRs), median times to event, and 95% CIs. Results In all, 107 patients were accrued: gemcitabine-docetaxel plus placebo (n = 54) and gemcitabine-docetaxel plus bevacizumab (n = 53). Accrual was stopped early for futility. No statistically significant differences in grade 3 to 4 toxicities were observed. Median PFS was 6.2 months for gemcitabine-docetaxel plus placebo versus 4.2 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.12; P = .58). Median OS was 26.9 months for gemcitabine-docetaxel plus placebo and 23.3 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.07; P = .81). Objective responses were observed in 17 (31.5%) of 54 patients randomly assigned to gemcitabine-docetaxel plus placebo and 19 (35.8%) of 53 patients randomly assigned to gemcitabine-docetaxel plus bevacizumab. Mean duration of response was 8.6 months for gemcitabine-docetaxel plus placebo versus 8.8 months for gemcitabine-docetaxel plus bevacizumab. Conclusion The addition of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improve PFS, OS, or ORR. Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele, Angela, Yee, Douglas , Berry, Donald A. , Albain, Kathy S. , Benz, Christopher C. , Buxton, Meredith , Chia, Stephen , Chien, A. Jo , Clark, Amy S. , Edmiston, Kirsten K., Forero‐Torres, Andres , Haddad, Tufia C. , Haley, Barbara , Haluska, Paul , Korde, Larissa A. , Leyland‐Jones, Brian , Liu, Minetta C. , Melisko, Michelle , Minton, Susan, Moulder, Stacy L. , Nanda, Rita , Olopade, Olufunmilayo I. , Paoloni, Melissa, Park, John W., Parker, Barbara A. , Perlmutter, Jane , Petricoin, Emanuel F. , Symmans, Fraser, Tripathy, Debasish , Veer, Laura J. van’t , Viscusi, Rebecca K., Symmans, W. Fraser , Boughey, Judy, Boughey, Judy C. , Hui, Jane Yuet Ching , Elias, Anthony , Hylton, Nola M. , Isaacs, Claudine , Kaplan, Henry G. , Rugo, Hope S. , Wallace, Anne M. , Wolf, Denise M. , Yau, Christina , Esserman, Laura J. , Olopade, Olufunmilayo I , Symmans, W Fraser , Yee, Douglas

Clinical Cancer Research | February 26, 2015 | Volume: 21 | Issue: 13 | Pages: 2911-2915

10.1158/1078-0432.ccr-14-1760 | PMID 25712686 Get It

AbstractThe many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach. Clin Cancer Res; 21(13); 2911–5. ©2015 AACR.